Clinic Software
About
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Founders
- Peter Glazer
- Elias Quijano
- Stephen Squinto
- Bruce Turner
Investors
News
- Daniel Bruno · 2026-06-27T17:28:19.000Z
- Chris Duke joins RBL LLC leadership team as Operating Partner · 2026-03-10T00:00:00.000Z
- Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer · 2025-07-16T00:00:00.000Z
- Next-gen cell-penetrating antibodies for tumor targeting and RAD51 inhibition | BrightSurf Science News · 2024-10-21T02:12:38.000Z
- RBL LLC Welcomes Chris Duke as New Operating Partner to Boost Biotech Ventures - Third News · 2026-03-10T12:27:09.000Z
- Former Assets of Gennao: Major Biotech Lab Auction - Federal Equipment Company Blog · 2025-01-29T21:41:11.000Z
